{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.0","value":"59.2"},{"groupId":"OG001","spread":"9.7","value":"49.6"},{"groupId":"OG002","spread":"13.1","value":"52.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"48"},{"groupId":"OG002","value":"22"}],"units":"Participants"}],"title":"Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.9","value":"54.3"},{"groupId":"OG001","spread":"12.3","value":"52.5"},{"groupId":"OG002","spread":"11.9","value":"49.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"44"},{"groupId":"OG002","value":"9"}],"units":"Participants"}],"title":"Prior to Maintenance Therapy"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.9","value":"55.3"},{"groupId":"OG001","spread":"10.1","value":"50.6"},{"groupId":"OG002","spread":"14.7","value":"45.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"40"},{"groupId":"OG002","value":"3"}],"units":"Participants"}],"title":"Completion of Therapy"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.7","value":"57.9"},{"groupId":"OG001","spread":"14.3","value":"56.5"},{"groupId":"OG002","spread":"20.0","value":"60.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"39"},{"groupId":"OG002","value":"9"}],"units":"Participants"}],"title":"12 Months Off Therapy"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.5","value":"59.9"},{"groupId":"OG001","spread":"13.6","value":"55.1"},{"groupId":"OG002","spread":"9.6","value":"52.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"37"},{"groupId":"OG002","value":"10"}],"units":"Participants"}],"title":"24 Months Off Therapy"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.8","value":"55.7"},{"groupId":"OG001","spread":"11.8","value":"57.7"},{"groupId":"OG002","spread":"11.1","value":"58.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"title":"36 Months Off Therapy"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.8","value":"60.3"},{"groupId":"OG001","spread":"11.7","value":"55.6"},{"groupId":"OG002","spread":"10.6","value":"49.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"33"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"title":"48 Months Off Therapy"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.8","value":"55.1"},{"groupId":"OG001","spread":"15.0","value":"58.3"},{"groupId":"OG002","spread":"13.4","value":"55.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"5"}],"units":"Participants"}],"title":"60 Months Off Therapy"}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"85"},{"groupId":"OG002","value":"34"}],"units":"Participants"}],"description":"Scores measuring executive functioning were obtained from Global Executive Composite (GEC) T-scores, which were obtained from the Behavior Rating Inventory of Executive Function (BRIEF) instrument which is a parent report. Higher scores indicate more problems. The normative mean is 50 with a standard deviation of 10.","dispersionType":"Standard Deviation","groups":[{"description":"Patients with gross total resection (GTR)/no evidence of metastatic (M0) medulloblastoma, nodular desmoplastic or high grade glioma histology will receive induction chemotherapy and low-risk therapy.","id":"OG000","title":"Low-Risk Group"},{"description":"Patients with M0 medulloblastoma or nodular desmoplastic histology with less than a GTR, other histologic diagnoses with no metastatic disease, will receive induction chemotherapy and intermediate-risk therapy.","id":"OG001","title":"Intermediate-Risk Group"},{"description":"Patients with central nervous system (CNS) metastatic disease will receive induction chemotherapy and high-risk therapy.","id":"OG002","title":"High-Risk Group"}],"paramType":"MEAN","populationDescription":"Eligible patients with scores at any of the data collection timepoints were included. Sample sizes differ across timepoints as not all subjects had scores for all timepoints.","reportingStatus":"POSTED","timeFrame":"Baseline, prior to maintenance therapy, completion of therapy, and 12 months, 24 months, 36 months, 48 months, and 60 months off therapy","title":"Neurocognitive Performance Related to Executive Functioning as Measured by Global Executive Composite T-scores","type":"SECONDARY","unitOfMeasure":"score on a scale"}